The IL-1 family in tumorigenesis and antitumor immunity

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

“… 29 The repeated intralesional strategy is considered feasible in the clinic; 62 hence we sought to improve its efficacy with the addition of other transgenes. Our screenings led to the identification of IL-18 63 as a suitable synergistic partner for the IL-12 mRNA transgene.…”

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy

“…The cytokines are the first to use the direct engagement of NKR to boost the immune response of NK cells for treating cancer disease. These include IL2, IL12, IL15, IL21, and type I IFNs but not for all [ 176 , 177 , 178 , 179 , 180 , 181 , 182 ]. Following cytokine treatment, NK cells convert (turn into) lymphokine-activated killer (LAK) cells, subsequently producing cytokines and upregulating the factors such as adhesion molecules, perforin, granzymes, FasL, and TRAIL [ 183 , 184 , 185 , 186 , 187 ], thereby enhancing their capability to detect and adhere to cancer cells, triggering various activity to eliminate cancer cells through perforin/granzyme-dependent necrosis [ 188 , 189 ] and/or Fasl/TRAIL-mediated apoptosis [ 184 , 185 , 186 , 187 ].…”

The role of NLRP3 inflammasome in digestive system malignancy

“…Although IL-1β and IL-18 belong to IL-1 family, they paly different roles in tumor biology and tumor immunity. Many studies have demonstrated that IL-1β can enhance tumor progression and resistance to cancer therapy; while IL-18 exerts an anti-tumor activity, as it can stimulate anti-tumor immunity by activating NK, Th1, CD4 + T cells, and CD8 + T cells (Sharma and Kanneganti, 2021;Sun et al, 2022).…”